Megan E Mcnerney

List of Publications by Year
in descending order

37 papers	1,729 citations	471509 17 h-index	414414 32 g-index
37 all docs	37 docs citations	37 times ranked	3165 citing authors

#	Article	IF	Citations
1	Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Reviews Cancer, 2017, 17, 513-527.	28.4	270
2	2B4 Acts As a Nonâ€"Major Histocompatibility Complex Binding Inhibitory Receptor on Mouse Natural Killer Cells. Journal of Experimental Medicine, 2004, 199, 1245-1254.	8.5	179
3	A new self: MHC-class-I-independent Natural-killer-cell self-tolerance. Nature Reviews Immunology, 2005, 5, 363-374.	22.7	156
4	CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood, 2013, 121, 975-983.	1.4	130
5	Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. Journal of Molecular Diagnostics, 2017, 19, 43-56.	2.8	105
6	Regulatory Defects in Cbl and Mitogen-Activated Protein Kinase (Extracellular Signal-Related Kinase) Pathways Cause Persistent Hyperexpression of CD40 Ligand in Human Lupus T Cells. Journal of Immunology, 2000, 165, 6627-6634.	0.8	90
7	2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Molecular Immunology, 2005, 42, 489-494.	2.2	90
8	Targeted Disruption of the<i>2B4</i>Gene in Mice Reveals an In Vivo Role of 2B4 (CD244) in the Rejection of B16 Melanoma Cells. Journal of Immunology, 2005, 174, 800-807.	0.8	88
9	Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood, 2006, 107, 3181-3188.	1.4	78
10	Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 969-975.	4.4	66
11	Widespread genetic epistasis among cancer genes. Nature Communications, 2014, 5, 4828.	12.8	63
12	Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in <i>Nras-</i>Driven Hematopoietic Transformation. Cancer Discovery, 2013, 3, 993-1001.	9.4	60
13	Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. PLoS Genetics, 2017, 13, e1006589.	3.5	53
14	2B4 (CD244)-CD48 interactions provide a novel MHC class I-independent system for NK-cell self-tolerance in mice. Blood, 2005, 106, 1337-1340.	1.4	50
15	Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature Genetics, 2015, 47, 539-543.	21.4	39
16	Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood, 2018, 131, 2682-2697.	1.4	36
17	The spectrum of somatic mutations in highâ€•risk acute myeloid leukaemia with â€•7/del(7q). British Journal of Haematology, 2014, 166, 550-556.	2.5	29
18	An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia. Seminars in Oncology, 2011, 38, 215-224.	2.2	21

#	Article	IF	Citations
19	The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters. Nucleic Acids Research, 2017, 45, 6350-6361.	14.5	21
20	Cytotoxic Therapyâ€"Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms. Blood Cancer Discovery, 2020, 1, 32-47.	5.0	16
21	Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica, 2016, 101, e232-e236.	3.5	13
22	Loss of a 7q gene,<i>CUX1</i>, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood, 2021, 138, 790-805.	1.4	13
23	Deficiency of <i>Cux1</i>, Encoded on Human Chromosome 7q, Causes Aberrant Hematopoietic Stem Cell Function and Spontaneous Myeloproliferative Disease in Mice. Blood, 2017, 130, 789-789.	1.4	10
24	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Advances, 2020, 4, 599-606.	5.2	9
25	System for Informatics in the Molecular Pathology Laboratory. Journal of Molecular Diagnostics, 2018, 20, 522-532.	2.8	8
26	Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death and Disease, 2021, 12, 1005.	6.3	8
27	Development of warm auto- and allo-antibodies in a 3-year old boy with sickle cell haemoglobinopathy following his first transfusion of a single unit of red blood cells. Blood Transfusion, 2010, 8, 126-8.	0.4	7
28	The significance of CUX1 and chromosome 7 in myeloid malignancies. Current Opinion in Hematology, 2022, 29, 92-102.	2.5	6
29	Deficiency of CUX1, Encoded on 7q, Blocks the Normal HSC DNA Damage Response and Drives Highly Penetrant Therapy-Related Myeloid Neoplasms in Mice. Blood, 2019, 134, 641-641.	1.4	5
30	The Harmful Consequences of Increased Fitness in Hematopoietic Stem Cells. Cell Stem Cell, 2018, 23, 634-635.	11.1	4
31	CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions. Leukemia, 2022, 36, 1421-1425.	7.2	3
32	Next-Generation Sequencing Analysis of 23 Therapy-Related Acute Myeloid Leukemia Transcriptomes. Blood, 2010, 116, 850-850.	1.4	2
33	Genomic studies controvert the existence of the CUX1 p75 isoform. Scientific Reports, 2022, 12, 151.	3.3	1
34	Natural killer cell subsets in allograft rejection and tolerance. Current Opinion in Organ Transplantation, 2007, 12, 10-16.	1.6	0
35	Retroviral Insertional Mutagenesis In Egr1+/- mice, Haploinsufficient For a Human Del(5q) Myeloid Leukemia Gene, Develop Myeloid Neoplasms With Proviral Insertions In Genes Syntenic To Human 5q. Blood, 2013, 122, 1275-1275.	1.4	0
36	Enhancer-Promoter Looping Deciphers Dosage of the Haploinsufficient Transcription Factor, CUX1. Blood, 2016, 128, 2700-2700.	1.4	0

#	Article	IF	Citations
37	CUX1 Deficiency Potentiates RAS Signaling to Drive Malignancy. Blood, 2021, 138, 1159-1159.	1.4	0